Rising Hypertension Fuels Growth In Acute Ischemic Stroke Therapeutics Market: Key Factor Driving The Growth In The Acute Ischemic Stroke Therapeutics Market

The Acute Ischemic Stroke Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Acute Ischemic Stroke Therapeutics Market Size During the Forecast Period?
The acute ischemic stroke therapeutics market has experienced significant growth in recent years. It is projected to rise from $9.24 billion in 2024 to $10.12 billion in 2025, at a compound annual growth rate (CAGR) of 9.5%. This growth during the historic period can be attributed to an increase in the number of patients, a growing geriatric population, rising obesity rates, a higher prevalence of ischemic stroke, and increasing cases of hypertension.

The market size for acute ischemic stroke therapeutics is projected to experience robust growth in the coming years. The forecast predicts a rise to $14.38 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this growth during the forecast period include a rising preference for online pharmacies, an increase in cardiovascular diseases, escalating cholesterol levels, an increased disease prevalence, and a growing incidence of ischemic stroke. Key trends for the forecast period include medical technology advancements, the incorporation of artificial intelligence and machine learning, advancements in neurology, and the embracement of advanced technological diagnostics.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19265

What Are the High-Growth Segments in the Acute Ischemic Stroke Therapeutics Market?
The acute ischemic stroke therapeuticsmarket covered in this report is segmented -

1) By Type: Thrombolytic Therapeutics, Antihypertensive Therapeutics, Antiplatelet Therapeutics, Anticoagulants
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hospitals, Ambulatory Surgical Center, Diagnostic Centers

Subsegments:
1) By Thrombolytic Therapeutics: Tissue Plasminogen Activators (tPA), Urokinase
2) By Antihypertensive Therapeutics: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Beta Blockers, Calcium Channel Blockers, Diuretics
3) By Antiplatelet Therapeutics: Aspirin, Clopidogrel, Ticagrelor, Dipyridamole, Cilostazol
4) By Anticoagulants: Vitamin K Antagonists, Direct Oral Anticoagulants (DOACs), Heparins

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19265&type=smp

What Key Drivers Are Expected to Influence Future Acute Ischemic Stroke Therapeutics Market Growth?
The anticipated increase in hypertension is predicted to fuel the expansion of the acute ischemic stroke therapeutics market. Hypertension, also known as high blood pressure, is a health condition characterized by a continual increase in the pressure of blood on the artery walls, heightening the likelihood of cardiac disease, stroke, and other associated health issues. The growing incidence of hypertension is chiefly attributed to an aging populace and a surge in obesity rates. Acute ischemic stroke therapeutics work to control escalating hypertension by tackling stroke-derived issues and averting additional cerebrovascular harm, frequently associated with high blood pressure. For example, as per the National Health Service England, a government agency based in the UK, approximately 30% of US adults were dealing with hypertension in May 2023, with 15% having hypertension that's not been treated. Furthermore, the frequency of hypertension rose with age, fluctuating from 9% in adults between 16 to 44 years old to 60% in those aged 65 and above. Consequently, the escalating rates of hypertension are stimulating the growth of the acute ischemic stroke therapeutics market.

Which Companies Hold the Largest Share Across Different Acute Ischemic Stroke Therapeutics Market Segments?
Major companies operating in the acute ischemic stroke therapeutics market are Johnson & Johnson, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Medtronic plc, Eli Lilly and Company, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Genentech Inc., NoNO Inc., Athersys Inc., XBiotech Inc., ZZ Biotech LLC

What Trends Are Driving Growth in The Acute Ischemic Stroke Therapeutics Market?
Major players in the acute ischemic stroke therapeutics market are prioritizing the development of state-of-the-art medical technologies via groundbreaking methodologies, such as exosome-based therapy for neurological indications. This innovative approach boosts the efficiency of the treatments and enhances patient outcomes. Central to this strategy is the use of exosomes - minuscule extracellular particles (30-150 nm in size) released by cells that take part in cellular communication. For example, Aruna Bio, a neural exosome platforms' developer based in the US, in January 2024, got the approval from the Food and Drug Administration (FDA) for the investigational new drug application for AB126. This marked the first exosome-based therapy to undergo human clinical trials for a neurological indication, specifically acute ischemic stroke. The Phase 1b/2a clinical trial is scheduled to commence in early 2024, concentrating on the safety, tolerability, and preliminary effectiveness of AB126 in post-thrombectomy patients with a grim outlook. AB126, culled from unique neural stem cells, can permeate the blood-brain barrier and demonstrated anti-inflammatory and neuroprotective impacts in preclinical studies.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-therapeutics-global-market-report

What Are the Emerging Geographies for The Acute Ischemic Stroke Therapeutics Market Growth?
North America was the largest region in the acute ischemic stroke therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute ischemic stroke therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acute Ischemic Stroke Therapeutics Market?
2. What is the CAGR expected in the Acute Ischemic Stroke Therapeutics Market?
3. What Are the Key Innovations Transforming the Acute Ischemic Stroke Therapeutics Industry?
4. Which Region Is Leading the Acute Ischemic Stroke Therapeutics Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.